Table 4.

Effects of atorvastatin therapy on 4-year risk of death from all causes in patients stratified according to baseline soluble urokinase plasminogen activator receptor levels

suPAR TertileHR95% CIP Value
Bottom0.890.67 to 1.180.40
Middle0.870.65 to 1.170.35
Top1.070.80 to 1.430.65
  • suPAR, soluble urokinase plasminogen activator receptor; HR, hazard ratio; 95% CI, 95% confidence interval.